Revvity, formerly known as PerkinElmer Informatics, is a leading provider of innovative software solutions headquartered in the United States. Established in 2022, the company has quickly positioned itself at the forefront of the life sciences and healthcare industries, focusing on data analytics, laboratory informatics, and scientific data management. With a commitment to enhancing research and development processes, Revvity offers a suite of core products that streamline workflows and improve data accessibility. Their unique approach combines advanced analytics with user-friendly interfaces, enabling organisations to make informed decisions swiftly. Recognised for its significant contributions to the field, Revvity continues to expand its operational reach, serving clients across North America and beyond. The company’s dedication to innovation and excellence has solidified its reputation as a trusted partner in the scientific community.
How does Revvity's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Revvity's score of 32 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Revvity, headquartered in the United States, reported total greenhouse gas emissions of approximately 29,810,000 kg CO2e for Scope 1 and 2 combined, with Scope 1 emissions at about 2,121,000 kg CO2e and Scope 2 emissions at approximately 27,689,000 kg CO2e (market-based). This represents a slight decrease from 2022, where total emissions were about 32,133,000 kg CO2e, with Scope 1 at approximately 2,289,000 kg CO2e and Scope 2 at about 29,844,000 kg CO2e (market-based). Revvity has set ambitious climate commitments, aiming for a 50% reduction in Scope 1 and 2 greenhouse gas emissions by 2033, starting from 2022 levels. Additionally, the company has pledged to achieve net carbon neutrality across all scopes by 2040. These targets reflect a long-term commitment to sustainability and align with industry standards for climate action. Revvity's emissions data is not cascaded from any parent organisation, indicating that the reported figures are independently sourced. The company is actively working towards its reduction goals and remains committed to enhancing its environmental performance in the pharmaceuticals, biotechnology, and life sciences sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 2,289,000 | 0,000,000 |
| Scope 2 | 29,844,000 | 00,000,000 |
| Scope 3 | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Revvity is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
